| Literature DB >> 32235852 |
Špela Bogataj1,2, Jernej Pajek1,3, Jadranka Buturović Ponikvar1,3, Vedran Hadžić2, Maja Pajek4.
Abstract
Intradialytic cycling is a widely used workout mode, whereas added benefit of other exercise modalities remains unknown. This is the first randomised controlled trial on the effects and sustainability of functional training and counselling in addition to intradialytic cycling. Patients were randomly assigned to a kinesiologist-guided functional training in addition to intradialytic cycling (n = 20, experimental group) or intradialytic cycling only (n = 20, control group) over 16 weeks. The experimental group attended predialysis functional exercise in the first eight weeks and afterward performed functional training at home for the next eight weeks. The primary study endpoint was 10-repetition-sit-to-stand test time at eight weeks: at this test, the experimental group improved significantly better than controls (-4.5 ± 1.9 s, 95%CI -8.4 to -0.7; P = 0.021), which was maintained at week 16 (-4.7 ± 2.1 s, 95%CI -9.0 to -0.3; P = 0.037). At week 8, the experimental group significantly outperformed controls also at handgrip strength (P = 0.004), lower body flexibility test (P < 0.001), balance test (P < 0.001), and upper body flexibility test (P = 0.003). At week 16, superior results of the experimental group in secondary end-points remained preserved for handgrip strength, balance, and upper body flexibility tests. Functional training with exercise counselling meaningfully improves physical performance and successfully prepares patients for sustainable home exercise.Entities:
Year: 2020 PMID: 32235852 PMCID: PMC7109131 DOI: 10.1038/s41598-020-62709-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow diagram of the randomized controlled study design.
Figure 2CONSORT (Consolidated Standards of Reporting Trials) diagram. *death (n = 1), sepsis (n = 1), fall and osteomuscular injury (n = 1), discontinued on patient’s demand; exacerbated symptoms of spinal stenosis (n = 1), **discontinued on patient’s demand (n = 1), coronary artery disease exacerbation with exertional dyspnea (n = 1), transplantation (n = 1).
Demographic and clinical characteristics.
| All participants (n = 40) | Experimental group (n = 20) | Control group (n = 20) | |
|---|---|---|---|
| Age (years) | 63.6 ± 12.5 | 65.2 ± 12.1 | 61.9 ± 13.0 |
| Male sex (%) | 55% | 60% | 50% |
| Height (cm) | 167.9 ± 9.8 | 168.4 ± 9.6 | 167.5 ± 10.2 |
| Weight (kg) | 72.1 ± 15.8 | 72.6 ± 16.1 | 71.7 ± 15.9 |
| Dialysis vintage (years) | 7.4 ± 7.7 | 7.4 ± 8.1 | 7.5 ± 7.3 |
| Weekly dialysis duration (h) | 12.9 ± 2.3 | 12.5 ± 2.7 | 13.3 ± 1.9 |
| Type of treatment (HD vs. HDF) | 15 vs. 25 | 9 vs. 11 | 6 vs. 14 |
| Lean tissue index (kg/m2) | 13.3 ± 2.6 | 13.6 ± 3.2 | 12.9 ± 2.0 |
| Fat tissue index (kg/m2) | 11.5 ± 5.4 | 11.4 ± 4.8 | 11.6 ± 6.1 |
| Phase angle (°) | 5.0 ± 0.9 | 5.2 ± 0.9 | 4.7 ± 0.9 |
| BIA assessed overhydration (L) | 1.4 ± 1.9 | 0.9 ± 1.1 | 1.9 ± 2.4 |
| Hemoglobin (g/L) | 120.2 ± 9.6 | 118 ± 7.3 | 122 ± 11.3 |
| Albumin (g/L) | 39.5 ± 2.9 | 39.4 ± 3.2 | 39.6 ± 2.5 |
| C-reactive protein (mg/L) | 9.2 ± 17.2 | 7.4 ± 14.2 | 11.0 ± 20.0 |
| Phosphorous (mmol/L) | 1.5 ± 0.5 | 1.5 ± 0.5 | 1.5 ± 0.5 |
| Systolic blood pressure (mm Hg) | 143 ± 15.4 | 141 ± 16.1 | 144 ± 14.93 |
| Diastolic blood pressure (mm Hg) | 81 ± 10.1 | 78 ± 10.2 | 84 ± 9.38 |
| Serum pre-dialysis creatinine (qmol/L) | 751 ± 148 | 750 ± 156 | 751 ± 143 |
| Urea (mmol/L) | 24 ± 5.8 | 22.6 ± 5.7 | 25.4 ± 5.73 |
| Davies comorbidity grade 0/1/2 ( | 27 (67.5)/9 (22.5)/4 (10) | 13 (65)/6 (30)/1 (5) | 14 (70)/3 (15)/3 (15) |
Note: Values are expressed as mean ± SD, number of subjects (percent). There were no statistically significant differences between the groups. Blood pressure was defined as the mean of the last three pre-dialysis blood pressure values. Phase angle measurements were performed with an 800 μA current at a frequency of 50 kHz.
Abbreviations: n, number of subjects; BIA, bioimpedance performed using Body Composition Monitor, Fresenius AG, Bad Homburg, Germany.
Adherence to training programs.
| Phase 1 | Phase 2 | |||
|---|---|---|---|---|
| Experimental group (n = 16) | Control group (n = 18) | Experimental group (n = 16) | Control group (n = 18) | |
| Intradialytic cycling | 90% ± 12% | 87% ± 10% | 82% ± 19% | 82% ± 13% |
| Functional training | 87% ± 12% | n/a | 73% ± 21%* | n/a |
| Cycling time (min/session) | 30.5 ± 8.3 | 31.8 ± 7.8 | 46.6 ± 17.0** | 44.4 ± 12.8** |
Note: Values are expressed as mean ± SD and characterize adherence to training programs defined as the total number of completed exercise sessions in contrast to a total number of sessions offered/advised. Abbreviations: n, number of subjects; n/a, not applicable; *P < 0.05 indicates significant within-group difference; **P < 0.01 indicates significant within-group difference.
Physical performance results during the study periods.
| Variable | Group | Baseline | 8 weeks | 16 weeks |
|---|---|---|---|---|
| 10 repetition sit-to-stand test (s) | EXP | 28.9 ± 6.5 | 18.9 ± 5.9** | 18.5 ± 5.8** |
| CON | 29.8 ± 8.8 | 25.9 ± 7.9** | 25.7 ± 9.1** | |
| 6-minute walk test (m) | EXP | 481 ± 99.6 | 551 ± 90.8** | 579 ± 96.7** |
| CON | 482 ± 96.8 | 498 ± 87.4** | 511 ± 100.2* | |
| Hand-grip strength test (kg) | EXP | 28.6 ± 8.1 | 34.4 ± 9.1** | 33.4 ± 9.5* |
| CON | 28.3 ± 6.1 | 27.7 ± 5.2 | 26.2 ± 5.7 | |
| Sit-and-reach test (cm) | EXP | 9.5 ± 7.1 | 14.3 ± 8.8** | 12.0 ± 9.1* |
| CON | 3.8 ± 10.4 | 4.4 ± 9.6 | 4.6 ± 10.5 | |
| Stork test (s) | EXP | 4.3 ± 9.4 | 9.1 ± 11.0** | 10.5 ± 14.1* |
| CON | 7.1 ± 9.2 | 9.0 ± 13.5 | 9.3 ± 13.9 | |
| Back scratch test (cm) | EXP | −14.0 ± 12.4 | −8.0 ± 12.2** | −9.0 ± 12.7** |
| CON | −10.9 ± 16.4 | −10.0 ± 17.5 | −8.9 ± 18.2* |
Note: Values are expressed as mean ± standard deviation. There were no statistically significant differences between groups at baseline. Abbreviations: EXP, experimental group; CON, control group. *P < 0.05 indicates significant within-group difference compared to the baseline value. **P < 0.01 indicates significant within-group difference compared to baseline value.
Figure 3Results of 10 repetition sit-to-stand test over time Note: (a) individual changes in 10 repetition sit-to-stand test for experimental group; (b) individual changes in 10 repetition sit-to-stand test for the control group; (c) changes of the mean in 10 repetition sit-to-stand test for both groups, summarized; *P < 0.05 indicates significant between-group difference. Abbreviations: EXP, experimental group; CON, control group; STS-10, 10 repetition sit-to-stand test.
Results of 8-week and 16-week ANCOVA: the difference between the experimental and control group.
| Variable | At 8 weeks | At 16 weeks | ||
|---|---|---|---|---|
| Difference (95% CI) | P value (EXP-CON) | Difference (95% CI) | P value (EXP-CON) | |
| 10 repetition sit-to-stand test | −4.5 ± 1.9 (−8.4 to −0.7) | 0.021 | −4.7 ± 2.1 (−9.0 to − 0.3) | 0.037 |
| 6-minute walk test | 9.5 ± 14.4 (−19.7 to 38.7) | 0.514 | 31.8 ± 19.7 (−8.4 to 72.0) | 0.117 |
| Hand-grip strength test | 3.7 ± 1.2 (1.3 to 6.2) | 0.004 | 4.3 ± 1.6 (1.1 to 7.5) | 0.01 |
| Sit-and-reach test | 5.8 ± 1.4 (2.9 to 8.6) | <0.001 | 2.7 ± 1.4 (−0.1 to 5.5) | 0.054 |
| Stork test (ln value) | 0.7 ± 0.2 (0.4 to 1.1) | <0.001 | 0.5 ± 0.2 (0.2 to 0.9) | 0.005 |
| Back scratch test | 5.8 ± 1.8 (2.2 to 9.5) | 0.003 | 3.8 ± 1.7 (0.4 to 7.3) | 0.032 |
Note: Values are expressed as mean ± standard deviation. Analysis for Stork test was performed on natural logarithm transformed values. All significant between-group differences with ANCOVA adjusted test were also significant with unadjusted between-group ANOVA test (P < 0.05). Abbreviations: EXP, experimental group; CON, control group; ANCOVA, analysis of covariance.
Adverse events encountered during the time of the study.
| Adverse event | EXP (n) | CON (n) | Comments |
|---|---|---|---|
| Low back pain | 2 | 1 | one early termination of cycling session and one of functional training due to lower back pain; one patient discontinued exercise due to worsening of spinal stenosis |
| Vascular access hematoma | 1 | 1 | two patients could not perform the cycling session due to hematoma not related to exercise |
| Hypotension episodes | 0 | 2 | one patient presented hypotension after a cycling session and one during the 6-min walk test |
| Fatigue episodes | 3 | 2 | three patients from the EXP group and two from the CON group prematurely stopped the exercise session due to fatigue |
| Muscle/joint pain | 0 | 1 | one patient’s intensity had to be reduced due to the exacerbation of hip pain |
| Hospitalization | 2 | 1 | two patients missed a few exercise sessions due to hospitalization not related to exercise; one patient discontinued intervention due to sepsis occurrence |
| MACE | 0 | 0 | |
| Death | 1 | 0 | one death (sepsis) |
Abbreviations: EXP, experimental group; CON, control group; n, number of events; MACE, major adverse cardiac events.